NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

FOSMANOGEPIX:新藥的考察與市場預測 (2030年)

FOSMANOGEPIX- Emerging Insight and Market Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 974746
出版日期 按訂單生產 內容資訊 英文 60 Pages
商品交期: 10個工作天內
價格
FOSMANOGEPIX:新藥的考察與市場預測 (2030年) FOSMANOGEPIX- Emerging Insight and Market Forecast - 2030
出版日期: 按訂單生產內容資訊: 英文 60 Pages
簡介

Fosmanogepix是一種新型的抗真菌藥物,可用於致命的真菌感染,例如念珠菌性芽孢桿菌病和曲霉病,目前正在進行II期試驗。它已被美國FDA(食品和藥物管理局)指定為7種適應症的快速通道和罕見病藥物,還被指定為4種適應症的認證傳染病產品(QIDP)。

本報告提供現在臨床實驗中的念珠菌性菌血症治療藥物FOSMANOGEPIX的市場結構·趨勢相關分析,提供產品概要 (用法·容量,作用機制等) 和相關法規,產品開發·臨床實驗的進展,主要7個國家 (美國,歐洲5個國家 (德國,法國,義大利,西班牙,英國),日本)的市場規模趨勢預測 (2020∼2030年),市場競爭狀態·SWOT分析,其他的治療藥的競爭狀態,資本交易的動向,今後的市場成長可能性等調查、考察。

目錄

第1章 醫藥品概要

  • 產品的詳細資訊
  • 作用機制
  • 用法·用量
  • 研究開發 (R&D) 活動
    • 臨床開發
    • 安全性和有效性
  • 其他開發活動

第2章 市場評估

  • 主要7個國家 (7MM)的市場分析
  • 美國市場
  • 德國市場
  • 法國市場
  • 義大利市場
  • 西班牙市場
  • 英國市場
  • 日本市場

第3章 SWOT分析

第4章 分析師的見解

第5章 市場參與企業

第6章 其他新治療方法

第7章 附錄

第8章 報告購買選擇

目錄
Product Code: DIDM0127

"FOSMANOGEPIX- Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Candidemia in 7 Major Markets. A detailed picture of the FOSMANOGEPIX in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

Overview:

Fosmanogepix, is a novel broad-spectrum antifungal agent being evaluated in multiple clinical trials in patients with life-threatening fungal infections. Enrollment was recently completed in a Phase 2 trial evaluating the safety and efficacy of the intravenous and oral formulations of fosmanogepix for the treatment of patients with Candida infections. In that study, fosmanogepix demonstrated a high level of treatment success in the first 10 patients treated. Additional Phase 2 studies of fosmanogepix are ongoing in patients with Aspergillus and other mold infections, as well as infections caused by multi-drug-resistant Candida auris, a life-threatening fungal infection recently characterized as an "urgent" threat by the Centers for Disease Control.

Fosmanogepix has a novel mechanism of action, and its active moiety has shown broad-spectrum activity against common species of Candida and Aspergillus, including multi-drug-resistant strains, such as C. auris and C. glabrata, as well as rare hard-to-treat molds including Fusarium, Scedosporium, and some fungi from the Mucorales order. Invasive fungal infections result in high mortality rates (30-80%), despite standard-of-care treatment. The frequency of fungi resistant to both the azole and echinocandin classes of drugs is increasing, and there is a significant unmet medical need for a new broad-spectrum antifungal agent.

Fosmanogepix has received Fast Track and Orphan Drug designations from the U.S. Food and Drug Administration for seven separate indications, and is designated as a Qualified Infectious Disease Product (QIDP) for the treatment of four indications.

Scope of the report:

The report provides insights into:

  • A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
  • Elaborated details on regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the drug research and development activity details across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around FOSMANOGEPIX.
  • The report contains forecasted sales for FOSMANOGEPIX till 2030.
  • Comprehensive coverage of the late-stage emerging therapies (Phase II) for Candidemia.
  • The report also features the SWOT analysis with analyst insights and key findings of FOSMANOGEPIX.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

FOSMANOGEPIX Analytical Perspective by DelveInsight

  • In-depth FOSMANOGEPIX Market Assessment

This report provides a detailed market assessment of FOSMANOGEPIX in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.

  • FOSMANOGEPIX Clinical Assessment

The report provides the clinical trials information of FOSMANOGEPIX covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights:

  • In the coming years, the market scenario for Candidemia is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence FOSMANOGEPIX dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Other emerging products for Candidemia are giving market competition to FOSMANOGEPIX and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of FOSMANOGEPIX.
  • Our in-depth analysis of the forecasted sales data of FOSMANOGEPIX from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the FOSMANOGEPIX.

Key Questions:

  • Which company is developing FOSMANOGEPIX along with the phase of the clinical study?
  • What is the technology utilized in the development of FOSMANOGEPIX?
  • What is the product type, route of administration and mechanism of action of FOSMANOGEPIX?
  • What is the clinical trial status of the study and study completion date?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the FOSMANOGEPIX development?
  • What are the key designations that have been granted to FOSMANOGEPIX?
  • What is the forecasted market scenario of FOSMANOGEPIX?
  • What is the history of FOSMANOGEPIX and what is its future?
  • What is the forecasted sales of FOSMANOGEPIX in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What are the other emerging products available and how these are giving competition to FOSMANOGEPIX?
  • Which are the late-stage emerging therapies under development for the treatment of the PPD?

Table of Contents

1. Drug Overview

  • 1.1. Product Detail
  • 1.2. Mechanism of Action
  • 1.3. Dosage and Administration
  • 1.4. Research and development activity
    • 1.4.1. Clinical Development
    • 1.4.2. Safety and Efficacy
  • 1.5. Other Development Activities

2. Market Assesment

  • 2.1. 7MM Market Analysis
  • 2.2. The United States Market
  • 2.3. Germany Market
  • 2.4. France Market
  • 2.5. Italy Market
  • 2.6. Spain Market
  • 2.7. United Kingdom Market
  • 2.8. Japan Market

3. SWOT Analysis

4. Analyst Views

5. Market Competitors

6. Other Emerging Therapies

7. Appendix

8. Report Purchase Options

List of Tables

  • Table 1: FOSMANOGEPIX, Description
  • Table 2: FOSMANOGEPIX, Clinical Trial Description
  • Table 3: FOSMANOGEPIX, 7MM Market Size from 2020 to 2030 (in Million USD)
  • Table 4: Market Competitors
  • Table 5: Other Emerging Therapies

List of Figures

  • Figure 1: The Development Timeline of FOSMANOGEPIX
  • Figure 2: Patent Details, FOSMANOGEPIX
  • Figure 3: FOSMANOGEPIX, 7MM Market Size from 2020 to 2030 (in Million USD)
  • Figure 4: FOSMANOGEPIX, US Market Size from 2020 to 2030 (in Millions USD)
  • Figure 5: FOSMANOGEPIX, EU5 Market Size from 2020 to 2030 (in Millions USD)
  • Figure 6: FOSMANOGEPIX, Japan Market Size from 2020 to 2030 (in Millions USD)